UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 37

Sortiert nach

Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial

Allergy (Copenhagen), 2021-06, Vol.76 (6), p.1789-1799

2021

Volltextzugriff (PDF)

Assessment of HAE prophylaxis transition from androgen therapy to berotralstat: a subset analysis of the APeX-S trial

The World Allergy Organization journal, 2023-11, Vol.16 (11), p.100841-100841, Article 100841

2023

Volltextzugriff (PDF)

Prophylaxis of hereditary angioedema attacks: A randomized trial of oral plasma kallikrein inhibition with avoralstat

Journal of allergy and clinical immunology, 2016-09, Vol.138 (3), p.934-936.e5

2016

Volltextzugriff (PDF)

Berotralstat for long-term prophylaxis of hereditary angioedema in Japan: Parts 2 and 3 of the randomized APeX-J Phase III trial

The World Allergy Organization journal, 2024-03, Vol.17 (3), p.100882-100882, Article 100882

2024

Volltextzugriff (PDF)

BCX4161, An Oral Kallikrein Inhibitor: Safety and Pharmacokinetic Results Of a Phase 1 Study In Healthy Volunteers

Journal of allergy and clinical immunology, 2014-02, Vol.133 (2), p.AB39-AB39

2014

Volltextzugriff (PDF)

Single dose peramivir for the treatment of acute seasonal influenza: integrated analysis of efficacy and safety from two placebo-controlled trials

Antiviral therapy, 2015-01, Vol.20 (7), p.709-719

2015

Volltextzugriff (PDF)

BCX7353, a Potent Inhibitor of Plasma Kallikrein, Shows Sustained Maximal Enzyme Inhibition When Dosed Orally Once Daily: Results from a Phase I Trial in Healthy Subjects

Journal of allergy and clinical immunology, 2016-02, Vol.137 (2), p.AB401-AB401

2016

Volltextzugriff (PDF)

A Simple, Sensitive and Selective Fluorogenic Assay To Monitor Plasma Kallikrein Inhibitory Activity Of BCX4161 In Activated Plasma

Journal of allergy and clinical immunology, 2014-02, Vol.133 (2), p.AB40-AB40

2014

Volltextzugriff (PDF)

Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema

The New England journal of medicine, 2018-07, Vol.379 (4), p.352-362

2018

Volltextzugriff (PDF)

Hereditary angioedema outcomes in US patients switched from injectable long-term prophylactic medication to oral berotralstat

Annals of allergy, asthma, & immunology, 2024-04, Vol.132 (4), p.505-511.e1

2024

Volltextzugriff (PDF)

Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients

Clinical infectious diseases, 2014-12, Vol.59 (12), p.e172-e185

2014

Volltextzugriff (PDF)

Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial

Journal of allergy and clinical immunology, 2021-07, Vol.148 (1), p.164-172.e9

2021

Volltextzugriff (PDF)

European Respiratory Society Clinical Practice Guideline on symptom management for adults with serious respiratory illness

The European respiratory journal, 2024-06, Vol.63 (6), p.2400335

2024

Volltextzugriff (PDF)

BCX9930, a Potent, Selective, Oral Factor D Inhibitor, Demonstrates Proof-of-Concept As Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Blood, 2020-11, Vol.136 (Supplement 1), p.14-15

2020

Volltextzugriff (PDF)

The opportunity for greater patient and public involvement and engagement in drug development and regulation

Nature reviews. Drug discovery, 2023-05, Vol.22 (5), p.337-338

2023

Volltextzugriff (PDF)

Remote consultations in primary care across low-, middle- and high-income countries: Implications for policy and care delivery

Journal of health services research & policy, 2023-07, Vol.28 (3), p.181-189

2023

Volltextzugriff (PDF)

Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS‐2 study

Allergy (Copenhagen), 2018-09, Vol.73 (9), p.1871-1880

2018

Volltextzugriff (PDF)

Absence of Pharmacokinetic Interaction Between Intravenous Peramivir and Oral Oseltamivir or Rimantadine in Humans

Journal of clinical pharmacology, 2012-09, Vol.52 (9), p.1410-1419

2012

Volltextzugriff (PDF)

Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized Trial

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2024-03, Vol.12 (3), p.733-743.e10

2024

Volltextzugriff (PDF)

Intravenous peramivir for treatment of influenza in hospitalized patients

Antiviral therapy, 2014-01, Vol.19 (4), p.349-361

2014

Volltextzugriff (PDF)

Efficacy Correlates with Plasma Levels in Opus-1, a Proof-of-Concept Study of Oral Kallikrein Inhibitor BCX4161 As a Prophylaxis Against Attacks of Hereditary Angioedema (HAE)

Journal of allergy and clinical immunology, 2015-02, Vol.135 (2), p.AB192-AB192

2015

Volltextzugriff (PDF)

BCX4161, an Oral Kallikrein Inhibitor, Showed Significant Benefits on Reducing Disease Burden and Improving Quality of Life in Subjects with Hereditary Angioedema in the Opus-1 Study

Journal of allergy and clinical immunology, 2015-02, Vol.135 (2), p.AB278-AB278

2015

Volltextzugriff (PDF)

1169Peramivir Safety in Hospitalized Influenza

Open forum infectious diseases, 2014-12, Vol.1 (suppl_1), p.S347-S348

2014

Volltextzugriff (PDF)

Single Dose IV Peramivir Treatment in Pediatric Influenza: Lack of Development of Influenza Virus Variants with Reduced Susceptibility to Peramivir

Open forum infectious diseases, 2017-10, Vol.4 (suppl_1), p.S520-S520

2017

Volltextzugriff (PDF)

Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC)

The Journal of infectious diseases, 1995-06, Vol.171 (6), p.1411

1995

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(35)
Buchkapitel
(2)

Sprache

Englisch
(36)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(17)
Life Sciences & Biomedicine
(16)
Humans
(11)
Immunology
(9)
Male
(8)
Adult
(7)
Female
(7)
Middle Aged
(7)
Allergy
(6)
Allergy And Immunology
(6)
Angioedema
(6)
Infectious Diseases
(6)
Quality Of Life
(6)
Berotralstat
(5)
Plasma Kallikrein
(5)
Prophylaxis
(5)
Treatment Outcome
(5)
Young Adult
(5)
Aged
(4)
Angioedemas, Hereditary - Prevention & Control
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial

Assessment of HAE prophylaxis transition from androgen therapy to berotralstat: a subset analysis of the APeX-S trial

Prophylaxis of hereditary angioedema attacks: A randomized trial of oral plasma kallikrein inhibition with avoralstat

Berotralstat for long-term prophylaxis of hereditary angioedema in Japan: Parts 2 and 3 of the randomized APeX-J Phase III trial

BCX4161, An Oral Kallikrein Inhibitor: Safety and Pharmacokinetic Results Of a Phase 1 Study In Healthy Volunteers

Single dose peramivir for the treatment of acute seasonal influenza: integrated analysis of efficacy and safety from two placebo-controlled trials

BCX7353, a Potent Inhibitor of Plasma Kallikrein, Shows Sustained Maximal Enzyme Inhibition When Dosed Orally Once Daily: Results from a Phase I Trial in Healthy Subjects

A Simple, Sensitive and Selective Fluorogenic Assay To Monitor Plasma Kallikrein Inhibitory Activity Of BCX4161 In Activated Plasma

Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema

Hereditary angioedema outcomes in US patients switched from injectable long-term prophylactic medication to oral berotralstat

Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients

Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial

European Respiratory Society Clinical Practice Guideline on symptom management for adults with serious respiratory illness

BCX9930, a Potent, Selective, Oral Factor D Inhibitor, Demonstrates Proof-of-Concept As Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

The opportunity for greater patient and public involvement and engagement in drug development and regulation

Remote consultations in primary care across low-, middle- and high-income countries: Implications for policy and care delivery

Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS‐2 study

Absence of Pharmacokinetic Interaction Between Intravenous Peramivir and Oral Oseltamivir or Rimantadine in Humans

Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized Trial

Intravenous peramivir for treatment of influenza in hospitalized patients

Efficacy Correlates with Plasma Levels in Opus-1, a Proof-of-Concept Study of Oral Kallikrein Inhibitor BCX4161 As a Prophylaxis Against Attacks of Hereditary Angioedema (HAE)

BCX4161, an Oral Kallikrein Inhibitor, Showed Significant Benefits on Reducing Disease Burden and Improving Quality of Life in Subjects with Hereditary Angioedema in the Opus-1 Study

1169Peramivir Safety in Hospitalized Influenza

Single Dose IV Peramivir Treatment in Pediatric Influenza: Lack of Development of Influenza Virus Variants with Reduced Susceptibility to Peramivir

Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC)

Suchergebnisse filtern